Recombinant
RabMAb

Recombinant Anti-Glucose Transporter GLUT1 antibody [EPR3915] (HRP) (ab195021)

Overview

  • Product name

    Anti-Glucose Transporter GLUT1 antibody [EPR3915] (HRP)
    See all Glucose Transporter GLUT1 primary antibodies
  • Description

    Rabbit monoclonal [EPR3915] to Glucose Transporter GLUT1 (HRP)
  • Host species

    Rabbit
  • Conjugation

    HRP
  • Tested applications

    Suitable for: IHC-P, WBmore details
  • Species reactivity

    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Glucose Transporter GLUT1 aa 450 to the C-terminus.

  • Positive control

    • WB: Mouse brain and Human fetal brain tissue lysates. IHC-P: normal human colon tissue.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab195021 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/5000. Detects a band of approximately 42 kDa (predicted molecular weight: 54 kDa).

Target

  • Function

    Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.
  • Tissue specificity

    Expressed at variable levels in many human tissues.
  • Involvement in disease

    Defects in SLC2A1 are the cause of glucose transporter type 1 deficiency syndrome (GLUT1DS) [MIM:606777]; also known as blood-brain barrier glucose transport defect. This disease causes a defect in glucose transport across the blood-brain barrier. It is characterized by infantile seizures, delayed development, and acquired microcephaly.
    Defects in SLC2A1 are the cause of dystonia type 18 (DYT18) [MIM:612126]. DYT18 is an exercise-induced paroxysmal dystonia/dyskinesia. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT18 is characterized by attacks of involuntary movements triggered by certain stimuli such as sudden movement or prolonged exercise. In some patients involuntary exertion-induced dystonic, choreoathetotic, and ballistic movements may be associated with macrocytic hemolytic anemia.
  • Sequence similarities

    Belongs to the major facilitator superfamily. Sugar transporter (TC 2.A.1.1) family. Glucose transporter subfamily.
  • Post-translational
    modifications

    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • Cellular localization

    Cell membrane. Melanosome. Localizes primarily at the cell surface (By similarity). Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
  • Information by UniProt
  • Database links

  • Alternative names

    • Choreoathetosis/spasticity episodic (paroxysmal choreoathetosis/spasticity) antibody
    • CSE antibody
    • DYT17 antibody
    • DYT18 antibody
    • DYT9 antibody
    • EIG12 antibody
    • erythrocyte/brain antibody
    • Erythrocyte/hepatoma glucose transporter antibody
    • facilitated glucose transporter member 1 antibody
    • Glucose transporter 1 antibody
    • Glucose transporter type 1 antibody
    • Glucose transporter type 1, erythrocyte/brain antibody
    • GLUT antibody
    • GLUT-1 antibody
    • GLUT1 antibody
    • GLUT1DS antibody
    • GLUTB antibody
    • GT1 antibody
    • GTG1 antibody
    • Gtg3 antibody
    • GTR1_HUMAN antibody
    • HepG2 glucose transporter antibody
    • HTLVR antibody
    • Human T cell leukemia virus (I and II) receptor antibody
    • MGC141895 antibody
    • MGC141896 antibody
    • PED antibody
    • RATGTG1 antibody
    • Receptor for HTLV 1 and HTLV 2 antibody
    • SLC2A1 antibody
    • Solute carrier family 2 (facilitated glucose transporter), member 1 antibody
    • Solute carrier family 2 antibody
    • Solute carrier family 2, facilitated glucose transporter member 1 antibody
    see all

Images

  • IHC image of Glucose Transporter GLUT1 staining in a section of formalin-fixed paraffin-embedded normal human colon tissue*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab195021 at 1/100 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

    *Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

  • All lanes : Anti-Glucose Transporter GLUT1 antibody [EPR3915] (HRP) (ab195021) at 1/5000 dilution

    Lane 1 : Brain (Mouse) Tissue Lysate
    Lane 2 : Brain (Human) Tissue Lysate - fetal normal tissue

    Lysates/proteins at 10 µg per lane.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 54 kDa
    Observed band size: 42 kDa
    why is the actual band size different from the predicted?


    Exposure time: 30 seconds


    This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab195021 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

References

ab195021 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab195021.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up